Related Experiment Videos
[Hemo- and lymphosorption in cardiogenic shock (an experimental study)]
Kardiologiia
|November 1, 1980
Summary
Toxemia significantly contributes to cardiogenic shock. Combining lymphosorption and hemosorption, while stimulating lymph flow, offers the most effective treatment for toxic shock.
Area of Science:
- Cardiovascular Pathophysiology
- Toxicology
- Renal Replacement Therapy
Context:
- Cardiogenic shock is a life-threatening condition characterized by the heart's inability to pump sufficient blood.
- Toxemia, the presence of toxins in the blood, plays a critical role in the development and progression of cardiogenic shock.
- Previous treatments have focused on either blood or lymph detoxification separately.
Purpose:
- To investigate the role of toxemia in cardiogenic shock pathogenesis.
- To evaluate the efficacy of lymphosorption and hemosorption, individually and in combination, for treating toxic cardiogenic shock.
- To determine optimal conditions for combined detoxification therapies.
Summary:
- Experiments on dogs demonstrated that toxemia is crucial in cardiogenic shock.
- Blood toxicity develops later than lymph toxicity.
- Lymphosorption halts toxemia progression but doesn't reverse established toxicity; hemosorption shows benefits but doesn't prevent toxic lymph inflow.
- Combined lympho- and hemosorption, with stimulated lymph production and drainage, yielded the best therapeutic effect.
Impact:
- Highlights the critical role of toxemia in cardiogenic shock.
- Establishes combined lympho- and hemosorption as a superior treatment strategy.
- Provides a basis for developing novel therapeutic approaches for toxic cardiogenic shock.